

Press release

Vetter's Clinical Facility Demonstrates Success with Five Client Products Now on the Market

US Skokie site addresses customer needs in early phase drug development


- **Clinical development pipeline is essential to global business strategy**
- **Vetter Development Service offers comprehensive expertise for in-human trial material**

Skokie, IL, February 01, 2023 – Drug development of novel therapeutics is increasing, and a growing number of pharmaceutical and biotech companies are seeking clinical manufacturing partners to meet the demand for complex fill and finish solutions. While the stages of early drug development are challenging, [Vetter](#), a leading global Contract Development and Manufacturing Organization (CDMO) is committed to addressing this challenge. The family-owned company offers comprehensive and expert manufacturing services for [clinical trials](#) to support a product's path to commercialization. A testament to this commitment is evidenced by the success of its [Skokie facility](#) located at the Illinois Science +Technology Park, which has already contributed to bring five new client products to market since it began full operations in 2011. Another four are expected to launch in the next months.

Since the site opened, 240+ customer audits have been successfully completed; the facility has performed over 45 media fills without failure. Vetter Development Service currently runs 80+ projects in phase I and II of clinical development. The US facility has executed 30+ transfers from its early clinical projects to Germany for late-stage development.

“Our clinical manufacturing sites are essential to Vetter’s commercial business pipeline. The Skokie site has demonstrated an impressive track record of success since its opening twelve years ago,” says Dr. Susanne Lemaine, Vice President Vetter Development Services US. “In the last year alone, we acquired more than 10 new customers with promising molecules. Overall, our ongoing investments in clinical filling capabilities are proof of Vetter’s consistent, strategic approach to keeping on track with the market, with a focus on the important drug development needs of our customers.”

Founded as a modest pharmacy in Ravensburg, Germany, in 1950, Vetter has grown from a local packager to a global contract development and manufacturing organization for injectable medication, today serving biotechnology and pharmaceutical customers both large and small.



© Vetter Pharma International GmbH: Supporting efficient drug development with dedicated clinical development expertise.



© Vetter Pharma International GmbH: Supporting efficient drug development with dedicated clinical development expertise.

Find the Vetter press kit and more background information [here](#).

About Vetter

Headquartered in Ravensburg, Germany, Vetter is a family-owned, global leading contract development and manufacturing organization (CDMO) with production facilities in Germany, Austria and the United States. Currently employing more than [5,700 individuals worldwide](#), the company has long-term experience in supporting biotechnology and pharmaceutical customers both large and small. Vetter [services](#) range from early stage development support including [clinical manufacturing](#), to [commercial supply](#) and [numerous packaging solutions](#) for vials, syringes and cartridges. As a leading solution provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety, convenience, and enhanced compliance. Great importance is also given to [social responsibility](#) including environmental protection and sustainability. Learn more about Vetter at www.vetter-pharma.com.

Contact

Vetter Pharma International GmbH
Markus Kirchner
Corporate Spokesperson / Media Relations
Eywiesenstrasse 5
88212 Ravensburg
Germany
Phone: +49 (0)751-3700-3729
E-mail: PRnews@vetter-pharma.com